Eumedica SA
155.6 FTEThe score of Eumedica shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +29 % Equity +86 % Total assets +42 % Headcount (avg FTE) +27 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Eumedica's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €81.2m | ||||
| Net result | €7.17m | ||||
| Equity | €26.3m | ||||
| Cash | €14.8m | ||||
| EBITDA | €12.2m | ||||
| Total assets | €61.2m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jul 2026
- Year ended 31 Dec 2024filed on 16 Jul 2025
- Year ended 31 Dec 2023filed on 23 Aug 2024
- Year ended 31 Dec 2022filed on 09 Aug 2023
- Year ended 31 Dec 2021filed on 14 Sep 2022
Eumedica's financial analysis
- Solvency43.0%sector median: 43.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Eumedica
Eumedica's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.057.665
- VAT number
- BE0403057665
- Peppol
- Registered · 0208:0403057665 · as of 22 Oct 2026
- Legal form
- SA
- Incorporated
- 01 Jan 1951
- Registered office
- 7170 Manage
- Size
- Medium · 155.6 FTE
- Latest accounts
- 2025 · filed on 15 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Eumedica (SA) has been based in Manage since 1951, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €81.2m, a net profit of €7.17m and equity of €26.3m. With 155.6 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 43.0%, below the median of its sector (43.4%).
Companies similar to Eumedica
Companies in the same business, of comparable size and area, outside its group.
- Centre Europeen DE Repartition Pharmaceutique Wholesale of pharmaceutical and medical goods Anderlecht · balance sheet €127.7m
- KCI Medical Belgium Wholesale of pharmaceutical and medical goods Peer · balance sheet €60.0m
- Gilead Sciences Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €68.7m
- sandoz Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €55.3m
- Servier Benelux Wholesale of pharmaceutical and medical goods Anderlecht · balance sheet €61.5m
- O&M Halyard Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €45.9m
- Zimmer Biomet Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €60.0m
- Covetrus Wholesale of pharmaceutical and medical goods Beringen · balance sheet €37.1m
Frequently asked questions about Eumedica
What is the revenue of Eumedica?
According to the 2025 annual accounts filed with the NBB, the revenue of Eumedica amounts to 81,209,185 €.
What is the VAT number of Eumedica?
In Belgium, the VAT number is the company number prefixed with BE: BE0403057665 for Eumedica, if the company is VAT-registered. Its company number (CBE) is 0403.057.665.
Where is the registered office of Eumedica?
According to the CBE register, the registered office of Eumedica is in 7170 Manage.
What is the equity of Eumedica?
At the close of the 2025 financial year, the equity of Eumedica amounts to 26,313,351 €, a solvency of 43.0% of total assets.
How many people work at Eumedica?
155.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Eumedica?
The register lists 5 active mandates at Eumedica. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Eumedica
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →